S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
NASDAQ:VRNA

Verona Pharma (VRNA) Competitors

$21.39
-0.16 (-0.74%)
(As of 05/26/2023 08:48 PM ET)
Compare
Today's Range
$21.20
$21.83
50-Day Range
$19.07
$23.43
52-Week Range
$3.85
$26.44
Volume
268,000 shs
Average Volume
582,125 shs
Market Capitalization
$1.69 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.33

VRNA vs. FGEN, IRWD, XNCR, DICE, RCKT, AUPH, ZNTL, AMLX, BLU, and GERN

Should you be buying Verona Pharma stock or one of its competitors? The main competitors of Verona Pharma include FibroGen (FGEN), Ironwood Pharmaceuticals (IRWD), Xencor (XNCR), DICE Therapeutics (DICE), Rocket Pharmaceuticals (RCKT), Aurinia Pharmaceuticals (AUPH), Zentalis Pharmaceuticals (ZNTL), Amylyx Pharmaceuticals (AMLX), BELLUS Health (BLU), and Geron (GERN). These companies are all part of the "pharmaceutical preparations" industry.

Verona Pharma vs.

Verona Pharma (NASDAQ:VRNA) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, community ranking, media sentiment, analyst recommendations, dividends and profitability.

76.9% of FibroGen shares are owned by institutional investors. 3.9% of Verona Pharma shares are owned by insiders. Comparatively, 2.8% of FibroGen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, FibroGen had 1 more articles in the media than Verona Pharma. MarketBeat recorded 4 mentions for FibroGen and 3 mentions for Verona Pharma. Verona Pharma's average media sentiment score of 0.93 beat FibroGen's score of 0.22 indicating that Verona Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Verona Pharma
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
FibroGen
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Verona Pharma has a net margin of 0.00% compared to FibroGen's net margin of -264.63%. Verona Pharma's return on equity of -28.33% beat FibroGen's return on equity.

Company Net Margins Return on Equity Return on Assets
Verona Pharma N/A -28.33% -23.95%
FibroGen -264.63% -879.75% -50.26%

Verona Pharma has higher earnings, but lower revenue than FibroGen. Verona Pharma is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verona Pharma$460 thousand3,673.04-$68.70 million-$0.96-22.28
FibroGen$140.73 million11.58-$293.65 million-$3.27-5.11

Verona Pharma has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

FibroGen received 44 more outperform votes than Verona Pharma when rated by MarketBeat users. However, 79.68% of users gave Verona Pharma an outperform vote while only 63.69% of users gave FibroGen an outperform vote.

CompanyUnderperformOutperform
Verona PharmaOutperform Votes
298
79.68%
Underperform Votes
76
20.32%
FibroGenOutperform Votes
342
63.69%
Underperform Votes
195
36.31%

Verona Pharma currently has a consensus price target of $29.33, indicating a potential upside of 37.14%. FibroGen has a consensus price target of $23.40, indicating a potential upside of 40.12%. Given FibroGen's higher possible upside, analysts clearly believe FibroGen is more favorable than Verona Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Verona Pharma
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
FibroGen
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Summary

Verona Pharma beats FibroGen on 11 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRNA vs. The Competition

MetricVerona PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.69B$5.67B$4.39B$6.16B
Dividend YieldN/A2.72%5.94%6.15%
P/E Ratio-22.289.43133.0414.49
Price / Sales3,673.04320.243,536.2686.88
Price / CashN/A20.3891.70107.21
Price / Book6.115.144.997.14
Net Income-$68.70M$185.80M$116.26M$192.57M
7 Day Performance0.28%-0.74%116.16%5.72%
1 Month Performance2.10%4.15%127.49%7.33%
1 Year Performance377.46%14.27%133.28%-0.52%

Verona Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FGEN
FibroGen
2.1366 of 5 stars
$17.40
+0.9%
$23.40
+34.5%
+66.2%$1.70B$140.73M-5.32566Short Interest ↑
IRWD
Ironwood Pharmaceuticals
2.2345 of 5 stars
$10.97
+1.1%
$14.00
+27.6%
-5.0%$1.69B$410.60M10.86219Analyst Revision
XNCR
Xencor
1.972 of 5 stars
$28.72
+3.4%
$45.00
+56.7%
+20.1%$1.73B$164.58M-12.27254
DICE
DICE Therapeutics
2.3031 of 5 stars
$34.11
-1.4%
$64.63
+89.5%
+118.9%$1.63B$1.13M-15.6546Short Interest ↓
RCKT
Rocket Pharmaceuticals
2.4136 of 5 stars
$22.24
+1.5%
$51.09
+129.7%
+83.4%$1.79BN/A-6.64151
AUPH
Aurinia Pharmaceuticals
2.1459 of 5 stars
$11.31
+0.3%
$13.00
+14.9%
-20.5%$1.62B$134.03M-16.88300Short Interest ↓
ZNTL
Zentalis Pharmaceuticals
1.5485 of 5 stars
$26.74
-2.1%
$46.00
+72.0%
+21.4%$1.59BN/A-6.23177Analyst Report
AMLX
Amylyx Pharmaceuticals
2.5356 of 5 stars
$27.40
+1.2%
$50.17
+83.1%
+182.8%$1.84B$22.23M-11.0534Short Interest ↑
BLU
BELLUS Health
2.0138 of 5 stars
$14.59
+1.0%
$16.50
+13.1%
+75.8%$1.85B$20,000.00-20.2640
GERN
Geron
2.0411 of 5 stars
$3.07
-2.5%
$5.00
+62.9%
+132.1%$1.56B$494,000.00-9.0369

Related Companies and Tools

This page (NASDAQ:VRNA) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -